WALTHAM, Mass., Oct. 27, 2016 (GLOBE
NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a
clinical-stage biopharmaceutical company focused on the development
of therapies to treat central nervous system (CNS) disorders, today
announced that it will release financial results and business
updates for the third quarter of 2016 on Thursday, November 3,
2016. The Company will host a webcast and conference call
that day at 8:30 a.m. Eastern Time to discuss these results and
updates.
The live call may be accessed by dialing (877)
312-5845 for domestic callers or (765) 507-2618 for international
callers and referring to conference ID number 90389179. A
live webcast of the conference call will be available online in the
Investors and Media section of the Company's website
at ir.minervaneurosciences.com. The archived webcast will be
available on the Company's website beginning approximately two
hours after the event for 30 days.
About Minerva
Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva's proprietary compounds include: MIN-101,
which has completed a Phase IIb clinical trial for schizophrenia;
MIN-117, which has completed a Phase IIa clinical trial development
for MDD; MIN-202 (JNJ-42847922), which has completed Phase
IIa and Phase Ib clinical trials for insomnia and MDD,
respectively; and MIN-301, in pre-clinical development for
Parkinson's disease. Minerva's common stock is listed on the
NASDAQ Global Market under the symbol "NERV." For more
information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376